GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of "Hold" by Brokerages

Key Points

• GoodRx Holdings, Inc. (NASDAQ:GDRX) has received a consensus rating of "Hold" from eleven ratings firms, with six analysts suggesting holding the stock and five recommending a buy.
• The company's latest earnings report showed a miss in EPS estimates, with $0.09 reported compared to the $0.10 anticipated by analysts, and revenue of $203.07 million falling short of expectations.
• Recent institutional activity includes significant increases in holdings by firms like EVR Research LP and Jane Street Group, with 63.77% of the stock now owned by institutional investors.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has received a consensus recommendation of "Hold" from the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $5.80.

GDRX has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. Raymond James Financial cut GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the firm's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $4.05, for a total transaction of $64,864.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.17% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GDRX. 8 Knots Management LLC bought a new position in GoodRx during the 1st quarter worth $8,106,000. EVR Research LP raised its position in GoodRx by 243.3% during the 1st quarter. EVR Research LP now owns 1,300,000 shares of the company's stock worth $5,733,000 after purchasing an additional 921,337 shares during the last quarter. Pathway Capital Management LP bought a new position in GoodRx during the 2nd quarter worth $2,906,000. Jane Street Group LLC grew its holdings in GoodRx by 481.5% during the 2nd quarter. Jane Street Group LLC now owns 487,887 shares of the company's stock worth $2,430,000 after acquiring an additional 403,981 shares during the period. Finally, LSV Asset Management acquired a new stake in GoodRx during the 2nd quarter worth about $1,900,000. 63.77% of the stock is owned by institutional investors.

GoodRx Stock Down 1.5%

NASDAQ GDRX opened at $4.07 on Tuesday. GoodRx has a fifty-two week low of $3.31 and a fifty-two week high of $7.20. The stock has a market capitalization of $1.41 billion, a PE ratio of 40.70, a PEG ratio of 1.80 and a beta of 1.23. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. The business has a fifty day moving average price of $4.35 and a two-hundred day moving average price of $4.40.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The firm had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The firm's revenue was up 1.2% on a year-over-year basis. Equities analysts expect that GoodRx will post 0.13 earnings per share for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.